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The myxoma virus (MYX) serpin SERP1 is a secreted glycoprotein with anti-inflammatory activity that is required for full
MYX virulence in vivo. The cowpox virus (CPV) serpin SPI-3 (vaccinia virus ORF K2L) is a nonsecreted glycoprotein that blocks
cell–cell fusion, independent of serpin activity, and is not required for virulence of vaccinia virus or CPV in mice. Although
SPI-3 has only 29% overall identity to SERP1, both serpins have arginine at the P1 position in the reactive center loop, and
SPI-3 has a proteinase inhibitory profile strikingly similar to that of SERP1 [Turner, P. C., Baquero, M. T., Yuan, S., Thoennes,
S. R., and Moyer, R. W. (2000) Virology 272, 267–280]. To determine whether SPI-3 and SERP1 were functionally equivalent,
a CPV variant was constructed where the SPI-3 gene was deleted and replaced with the SERP1 gene regulated by the SPI-3
promoter. Cells infected with CPVDSPI-3<SERP1 secrete SERP1 and show extensive fusion, suggesting that SERP1 is unable
to functionally substitute for SPI-3 in fusion inhibition. In the reciprocal experiment, both copies of SERP1 were deleted from
MYX and replaced with SPI-3 under the control of the SERP1 promoter. Cells infected with the MYXDSERP1<SPI-3
recombinant unexpectedly secreted SPI-3, suggesting either that the cellular secretory pathway is enhanced by MYX or that
CPV encodes a protein that prevents SPI-3 secretion. MYXDSERP1<SPI-3 was as attenuated in rabbits as
MYXDSERP1<lacZ, indicating that SPI-3 cannot substitute for SERP1 in MYX pathogenesis. © 2000 Academic PressINTRODUCTION
Collectively, poxviruses share a number of character-
istics including replication within the cytoplasm of the
host cells and a large double-stranded DNA genome
with closed hairpin termini (Moss, 1996). However, the
diseases caused by these viruses (Fenner, 1996) vary
from restricted and relatively benign (e.g., swinepox and
molluscum contagiosum) to systemic and with a high
mortality rate (e.g., myxomatosis and smallpox). Early
during infection the host defenses are mostly nonspe-
cific and include inflammation, the cytolytic action of
natural killer cells, the activation of cytokines and che-
mokines, and programmed cell death. Poxviruses en-
code a number of proteins that deflect these host re-
sponses (Nash et al., 1999; Pickup, 1994; Smith et al.,
1997).
Members of the serpin superfamily of serine protein-
ase inhibitors are included among these poxvirus immu-
nomodulatory proteins. Serpins regulate a variety of bi-
ological processes dependent on proteinases, including
the maturation of proinflammatory cytokines, apoptosis,
complement activation, fibrinolysis, blood clotting, and
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Molecular Genetics and Microbiology, Col-ege of Medicine, University of Florida, Box 100266, Gainesville, FL
2610-0266. Fax: (352) 846-2042. E-mail: rmoyer@ufl.edu.
281tissue remodeling (for a review see Potempa et al., 1994).
Despite the widespread use of serpins to control cellular
pathways, poxviruses are the only family of viruses
known to encode functional serpins.
Serpins inhibit specific proteinases by acting as
pseudosubstrates. A key region of the serpin that resem-
bles the substrate normally recognized by the proteinase
is the reactive center loop (RCL), located near the C-
terminus. The RCL protrudes from the surface of the
globular serpin and contains a key residue (P1) respon-
sible for proteinase specificity. Inhibition of the protein-
ase is initiated when the proteinase attacks the bond
between the P1 and adjacent P19 residues of the serpin,
leading to the formation of a stable serpin/proteinase
complex (Potempa et al., 1994).
The leporipoxvirus myxoma virus (MYX) causes a
rapid and fatal systemic disease (myxomatosis) in the
European rabbit (Oryctolagus cuniculus) that includes
immunosuppression (Fenner, 1996; McFadden, 1994).
The MYX genome has been completely sequenced
(Cameron et al., 1999) and encodes two intact serpins
known as SERP1 (Macen et al., 1993; Upton et al., 1990)
and SERP2 (Messud-Petit et al., 1998; Petit et al., 1996),
together with a truncated serpin SERP3. The SERP2
protein has some resemblance to the crmA/SPI-2 serpin
encoded by the orthopoxviruses in that it has been re-
ported to inhibit the interleukin-1b convertase (ICE) (Petit
et al., 1996). SERP2 mutants of MYX are strongly atten-
0042-6822/00 $35.00
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282 WANG ET AL.uated (Messud-Petit et al., 1998), indicating that the nat-
ral target of the SERP2 protein plays an important role
n host defense against myxoma virus.
The myxoma SERP1 protein (Macen et al., 1993; Nash
et al., 1997; Upton et al., 1990) is also required for full
virulence of wild-type myxoma virus. Mutation of both
copies of the SERP1 gene within the terminal inverted
repeats results in a significant attenuation of myxoma
virus, such that more than half of the infected animals are
able to recover from an otherwise lethal infection (Macen
et al., 1993). A mutant of malignant rabbit fibroma virus in
which SERP1 had been inactivated was also attenuated
relative to wild type (Upton et al., 1990).
The SERP1 protein has been shown to be involved in
the suppression of inflammation following infection with
wild-type myxoma virus (Macen et al., 1993). Purified
SERP1 protein has proved to have potent anti-inflamma-
tory activity in animal models of arthritis (Maksymowych
et al., 1996) and to inhibit restenosis following angio-
plasty (Lucas et al., 1996). SERP1 is a secreted glyco-
protein that is expressed late during infection (Macen et
al., 1993) and has been shown to inhibit the serine
proteinases plasmin, urokinase, and tissue plasminogen
activator (tPA) in vitro (Lomas et al., 1993) and also
thrombin and factor Xa (Nash et al., 1998), consistent
with the P1/P19 sequence of Arg/Asn. Whether any one
of these inhibited proteinases is the true “natural target”
of SERP1 is not clear.
The orthopoxviruses (e.g., variola, cowpox, vaccinia,
and rabbitpox viruses) encode three serpins. The crmA/
SPI-2 protein is a potent inhibitor of ICE (caspase-1) (Ray
et al., 1992) and of some other caspases (Zhou et al.,
1997), thus conferring both anti-inflammatory and anti-
apoptosis activities (Bird, 1998; Cohen, 1997). CrmA is
termed a cross-class proteinase inhibitor because it in-
hibits both cysteine proteinases and the serine protein-
ase granzyme B (Quan et al., 1995). A second orthopox-
virus serpin, SPI-1, is associated with the maintenance of
full host range and inhibiting the chymotrypsin-like pro-
teinase cathepsin G (Moon et al., 1999).
The third orthopoxvirus serpin SPI-3 (ORF K2L in vac-
cinia virus) is known to inhibit cell–cell fusion following
infection (Law and Smith, 1992; Turner and Moyer, 1992a;
Zhou et al., 1992). SPI-3, like SERP1, has extensive N-
linked glycosylation, but unlike SERP1 is expressed at
early times in infection (Turner and Moyer, 1995) and is
not secreted. Although SPI-3 and SERP1 share only 29%
overall identity, typical of any two unrelated serpins,
SPI-3 is predicted to have the same P1 Arg residue.
However, unlike SERP1, SPI-3 does not appear to be
required for virulence as SPI-3 deletion mutants in vac-
cinia virus (VV) and cowpox virus (CPV) inoculated intra-
nasally were as lethal in mice as wild-type viruses (Law
and Smith, 1992; Thompson et al., 1993). Despite the
SPI-3 protein having all the features characteristic of an
inhibitory serpin, analysis by site-directed mutagenesis
3
eindicated that these motifs were not required for the
SPI-3 protein to inhibit cell fusion (Turner and Moyer,
1995).
We have shown that SPI-3 protein, like SERP1, is able
to form stable complexes with and inhibit the protein-
ases plasmin, urokinase, and tPA (Turner et al., 2000). As
with SERP1, some complex formation is also noted be-
tween SPI-3 and thrombin or factor Xa (Nash et al., 1998).
Hence, the overall inhibitory spectrum of SPI-3 appears
to be very similar to that of SERP1, suggesting that these
two proteins may have a similar function in vivo. There-
fore, SERP1 was tested for its ability to substitute for
SPI-3 in cowpox virus in suppressing cell fusion, and
SPI-3 was tested for the ability to function in place of
SERP1 in conferring full virulence on myxoma virus.
When the ORFs were exchanged between the two vi-
ruses the natural promoters were left intact in each case,
such that the CPV recombinant expressed SERP1 from
the early SPI-3 promoter, and the MYX recombinant ex-
pressed SPI-3 from the late SERP1 promoter. Our results
indicate that SERP1 could not substitute for SPI-3 and
vice versa, despite the similar biochemical activity of the
two serpins in vitro.
RESULTS
Construction and characterization of a CPV
recombinant deleted for SPI-3 and expressing SERP1
as an early protein
The recombinant virus CPVDSPI-3<SERP1 was cre-
ated following transfection of wtCPV infected cells with
the plasmid pPSPI-3-SERP1-P7.5gpt (Materials and Meth-
ds), which allows deletion of the SPI-3 ORF and re-
lacement by the SERP1 ORF under the control of the
PI-3 early promoter. This plasmid also introduces the
pt gene downstream of the SERP1 gene (Fig. 1), en-
bling selection of recombinants by mycophenolic acid
esistance. Deletion of the SPI-3 gene was confirmed by
oth Western blot and PCR analysis, and insertion of the
ERP1 ORF was verified by PCR (data not shown). Ex-
ression of SERP1 by CPVDSPI-3<SERP1 was initially
onfirmed by immunoblotting of intracellular and extra-
ellular fractions from infected cells with SERP1 mono-
lonal antibody (Fig. 2A). No SERP1 was detected in
xtracts of mock or wtCPV infected cells as expected
Fig. 2A, lanes 1–4). An immunopositive band of approx-
mately 55 kDa was present in the supernatants of cells
nfected with the CPVDSPI-3<SERP1 recombinant and
rom control wtMYX infected cells (Fig. 2A, lanes 6 and 8).
ittle if any SERP1 was detected in the cellular fraction of
hese cells (Fig. 2A, lanes 5 and 7), indicating that as
xpected most of the SERP1 was secreted when ex-
ressed from either virus. To investigate the possibility
hat SERP1 is present in the supernatants of CPVDSPI-
<SERP1 infected cells as a constituent of extracellular
nveloped virus (EEV) rather than as an independently
t
i
l
a
b
M
b a recom
i
283FUNCTIONAL EXCHANGE OF SERP1 AND SPI-3secreted protein, the medium harvested from infected
RK-13 cells was further fractionated by high-speed cen-
trifugation under conditions that sediment EEV. SERP1
was found solely in the cleared supernatant of cells
infected with CPVDSPI-3<SERP1, and none was de-
tected in the pellet fraction that contains EEV (data not
shown). Hence, expression of SERP1 from within a CPV
context does not alter the natural secretion pattern of
SERP1 seen in MYX infected cells.
The SPI-3 gene of CPV is normally expressed early
prior to DNA synthesis (Smith et al., 1989; Turner and
Moyer, 1995), whereas MYX SERP1 is a late gene, ex-
pressed only after DNA synthesis (Macen et al., 1993).
The recombinant CPVDSPI-3<SERP1 was designed so
that the SERP1 ORF would be regulated by the SPI-3
promoter and hence should be expressed early. SERP1
expression in CPVDSPI-3<SERP1 infected cells was
FIG. 1. Construction of the recombinant cowpox and myxoma viruses
is shown within the wild-type CPV HindIII genomic map (Mackett and Ar
he map, the structure of CPVDSPI-3<SERP1 is represented with SER
nserted downstream of the SERP1 gene to facilitate selection of recom
ocation of the region within the TIR encoding the SERP1 gene and nei
nd Robbins, 1989). Note that there is an overlap of 23 bp between the
ulk of the SERP1 ORF (excluding the region that overlaps M-T8)
YXDSERP1<SPI-3, the CPV SPI-3 gene is expressed from the late S
y resistance to mycophenolic acid. The reconstructed wild-type myxom
n the text.evaluated in the presence or in the absence of cytosine
arabinoside (AraC), an inhibitor of viral DNA synthesisand late gene expression. Supernatants were harvested
at 4, 8, 12, and 16 h postinfection (p.i.) and analyzed by
immunoblot analysis with SERP1 monoclonal antibody.
SERP1 protein was present in the supernatants of in-
fected cells harvested at 8, 12, and 16 p.i., both in the
absence (Fig. 2B, lanes 3, 5, and 7) and in the presence
(lanes 4, 6, and 8) of AraC. Little or no SERP1 was
present in the infected cell pellets (data not shown),
indicating that secretion was very efficient. These data
indicate that SERP1 is being expressed early by
CPVDSPI-3<SERP1 and show that SERP1 is secreted
whether synthesized early in CPV or late in MYX.
SERP1 fails to substitute for SPI-3 in inhibiting cell–
cell fusion in CPV infected cells
One of the known functions of SPI-3 protein is to inhibit
map position of the SPI-3 gene (equivalent to vaccinia virus ORF K2L)
1979). Gray boxes represent the terminal inverted repeats (TIRs). Below
er the control of the early SPI-3 promoter. The P7.5-gpt cassette was
viruses. (B) The structures of myxoma virus derivatives are shown. The
g ORFs M-T9 and M-T8 is shown below the MYX HindIII map (Russell
of the SERP1 ORF and the 59 end of M-T8. In MYXDSERP1<lacZ the
en replaced by the lacZ gene driven by the CPV ATI promoter. In
romoter. Recombinants containing the P7.5-gpt cassette were selected
binant (rwtMYX2) was derived from MYXDSERP1<SPI-3 as described. (A) The
chard,
P1 und
binant
ghborin
39 end
has be
ERP1 pinfected cell–cell fusion (Law and Smith, 1992; Turner
and Moyer, 1992a; Zhou et al., 1992). The ability of SPI-3
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284 WANG ET AL.to control cell fusion does not depend on the RCL of the
serpin, indicating that serpin activity and control of fusion
are two independent functions of the protein (Turner and
Moyer, 1995). As the orthopoxvirus hemagglutinin also
inhibits fusion (Ichihashi and Dales, 1971) and is glyco-
sylated, we hypothesized that the presence of N-linked
glycosylation may be connected with fusion inhibition.
FIG. 2. Expression of SERP1 by CPVDSPI-3<SERP1 in the presence
nd in the absence of AraC. (A) RK-13 cells were infected with the
ndicated viruses at an m.o.i. of 10, harvested at 20 h postinfection, and
ractionated into cell-associated pellet (P) and supernatant (S) fractions
y low-speed centrifugation. The supernatants were concentrated by
ltrafiltration as described under Materials and Methods. Proteins
ithin the pellet and supernatant fractions were subjected to Western
lot analysis using anti-SERP1 sera following separation on SDS–
olyacrylamide gels. Lane 1, cell-associated pellet from mock-infected
ells; lane 2, supernatant from mock-infected cells; lanes 3 and 4, pellet
nd supernatant, respectively, from wtCPV infected cells; lanes 5 and 6,
ellet and supernatant from CPVDSERP1<SPI-3 infection; lanes 7 and
, pellet and supernatant from cells infected with wtMYX. (B) RK-13 cells
ere infected with CPVDSPI-3<SERP1 at an m.o.i. of 10 in the pres-
nce or in the absence of 40 mg/ml AraC. The infected cell superna-
tants were collected at the times postinfection indicated above each
lane and concentrated. Expression of SERP1 was assayed by Western
blotting of proteins separated on SDS–polyacrylamide gels. Duplicate
samples of infected cells were prepared either in the absence (lanes 1,
3, 5, and 7) or in the presence (lanes 2, 4, 6, and 8) of AraC.We asked whether the glycoprotein SERP1 can substi-
tute for SPI-3 to prevent fusion of CPVDSPI-3<SERP1infected cells. Monolayers of CV-1 cells were infected at
low multiplicity with wtCPV, CPVDSPI-3, or CPVDSPI-
3<SERP1 under liquid medium and examined 24 h
postinfection. The plaques formed in cells infected with
CPVDSPI-3<SERP1 (Fig. 3C) show extensive fusion as
do CPVDSPI-3 plaques (Fig. 3B) and were clearly differ-
entiated from wild-type CPV plaques, which produced
minimal cytopathic effect and no fusion under these
conditions (Fig. 3A). Plaques of CPVDSPI-3<SERP1 were
still able to hemadsorb chicken red blood cells (data not
shown); i.e., they expressed a functional hemagglutinin
as expected. The fact that CPVDSPI-3<SERP1 is fuso-
genic is therefore not due to an unintended mutation in
the HA gene, but rather indicates that SERP1 is unable to
substitute for SPI-3 to inhibit fusion in CPV infected cells.
Replacement of the myxoma virus SERP1 gene with
the cowpox virus SPI-3 gene
Although SERP1 has a role in MYX virulence, the gene
is dispensible for replication of MYX in tissue culture
(Macen et al., 1993; Upton et al., 1990). Since the spec-
rum of inhibited proteinases appears similar between
PI-3 and SERP1 (Turner et al., 2000), we asked whether
ERP1 could be functionally replaced by SPI-3. SERP1 is
resent in two copies within the inverted repeat regions
f MYX. Therefore, we first constructed a MYX deletion
utant (MYXDSERP1<lacZ; Fig. 1) in which both copies
f SERP1 were replaced with the lacZ gene under the
ontrol of the CPV ATI promoter. This mutant provides a
ontrol for the effect of SERP1 on virulence of the virus
nd was obtained by infecting RK-13 cells with wild-type
YX and transfecting with pSERP1-ATI/lacZ plasmid
NA (Materials and Methods). Several recombinant
laques expressing lacZ, based on X-gal staining, were
icked and replaqued several times until all the resulting
rogeny were blue. This procedure maximizes the like-
ihood that both copies of SERP1 have been replaced by
acZ, as heterozygotes when replaqued yield a mixture of
oth white and blue plaques. Potential MYXDSERP1<lacZ
ecombinants were tested by both PCR and immunoblot-
ing to verify that both copies of the SERP1 gene had
een removed and that there was no expression of
ERP1 (data not shown).
Virus in which the lacZ gene was replaced by SPI-3 to
enerate MYXDSERP1<SPI-3 (Fig. 1) was generated by
ransfecting pPSERP1-SPI-3-P7.5gpt transfer plasmid DNA
into RK13 cells infected with MYXDSERP1<lacZ followed
by selection for mycophenolic acid-resistant plaques.
The initial recombinants were still lacZ positive as pre-
sumably only one copy of the lacZ gene had been re-
placed by the SPI-3-gpt cassette. Individual plaques
were replaqued three times in the presence of mycophe-
nolic acid, which resulted in isolates yielding only white
plaques, consistent with replacement of both copies of
the lacZ gene with the SPI-3-gpt cassette. This virus
p ostinfe
w
285FUNCTIONAL EXCHANGE OF SERP1 AND SPI-3(MYXDSERP1<SPI-3) was shown to lack the SERP1 and
lacZ genes by PCR and to lack SERP1 expression by
immunoblot analysis (not shown). In order to confirm that
any effects of deleting SERP1 and replacing with SPI-3
were not due to unintended mutations, a reconstructed
wild-type virus (rwtMYX2) was obtained by infecting with
MYXDSERP1<SPI-3, transfecting with a plasmid clone
containing the wtSERP1 gene and flanks, and selecting
for recombinants that had lost the gpt cassette by re-
verse selection for resistance to 6-thioguanine (Isaacs et
al., 1990) using HGPRT2 HeLa cells (Kerr et al., 1991).
rwtMYX2 expressed SERP1 protein in the supernatant as
anticipated.
Secretion of SPI-3 by MYXDSERP1<SPI-3 infected
cells
The presence of the SPI-3 gene in MYXDSERP1<SPI-3
was confirmed by PCR (data not shown), and expression
of SPI-3 protein was assessed by Western blot analysis
of infected cells, examining both cell pellets and low-
speed supernatants (Fig. 4). As expected, no synthesis of
SPI-3 was noted in mock or wtMYX infected cells (Fig. 4,
lanes 1, 2 and 8, 9). No SPI-3 was present in the cell
pellet after infection with MYXDSERP1<SPI-3 (Fig. 4,
lane 7), but instead SPI-3 was found in the supernatant
as 57- and 55-kDa proteins (Fig. 4, lane 3). To evaluate
the possibility that the SPI-3 protein produced by
MYXDSERP1<SPI-3 was not truly secreted, but rather
associated with released EEV, medium from infected
RK-13 cells was collected at 20 h postinfection and sep-
arated into cleared supernatant and extracellular virus
fractions by high-speed centrifugation. SPI-3 was found
exclusively in the high-speed supernatant, indicating that
it was not associated with EEV and was a true secreted
FIG. 3. CPV-mediated fusion of infected cells. Confluent monolayers
laques were photographed using phase-contrast microscopy at 24 h p
tCPV. (B) CPVDSPI-3. (C) CPVDSPI-3<SERP1.protein (data not shown).
SPI-3 in CPV infected cells is normally expressed insmall amounts and is not secreted (Turner and Moyer,
unpublished data). For the comparisons shown here, the
vaccinia/T7 expression system (Fuerst et al., 1986) was
used to overexpress SPI-3 to ensure reproducibly detect-
able levels of SPI-3. As previously reported (Turner and
Moyer, 1995), vTF7-3 and VV-PT7–SPI-3 mixed infections
produce a large amount of SPI-3 that migrates as 50- and
cells were infected at low multiplicity in liquid medium and individual
ction. A single representative plaque is shown from each infection. (A)
FIG. 4. Comparison of SPI-3 synthesized by vaccinia/T7 expression
and by MYXDSERP1<SPI-3. RK-13 cells were infected either with
vTF7-3 and VV-PT7-SPI-3 (for expression in the VV/T7 system) or with
wtMYX or MYXDSERP1<SPI-3. Infected cells were harvested at 20 h
postinfection, separated into supernatant and cell-associated pellet
fractions, and subjected to Western blot analysis with anti-SPI-3 sera.
Lanes 1–4 are from supernatants, and lanes 5–9 are from cell pellets,
as indicated above the blot. Lanes 1 and 9, mock-infected RK-13 cells;
lanes 2 and 8, wtMYX infected cells; lanes 3 and 7, MYXDSERP1<SPI-3of CV-1infected cells. Lanes 4 and 5 are from cells coinfected with vTF7-3 and
VV-PT7-SPI-3. Lane 6 is the cell pellet from infection with vTF7-3 alone.
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286 WANG ET AL.48-kDa glycosylated proteins. This overexpressed SPI-3,
like naturally expressed SPI-3, remains within the cell
(Fig. 4, lane 5) and was not found in the cleared super-
natant (Fig. 4, lane 4). Hence within the context of vac-
cinia virus, no overexpressed SPI-3 was secreted.
The extent of SPI-3 glycosylation is different in MYX
and VV infected cells
Inspection of the data of Fig. 4 shows that the SPI-3
protein secreted from MYXDSERP1<SPI-3 infected cells
ppears somewhat larger than the SPI-3 synthesized
rom vaccinia virus (Fig. 4, compare lanes 3 and 5). Since
K-13 cells were the host cells in both cases, this differ-
nce is dependent on the context (orthopoxvirus or lepo-
ipox virus) in which SPI-3 is expressed. The difference in
pparent molecular weights between the SPI-3 proteins
ynthesized by the MYX recombinant and by the vaccin-
a/T7 system might be due to differences in the extent of
-linked glycosylation of SPI-3, which has four potential
ites for modification. N-linked glycosylation of SPI-3
solated from vTF7-3 and VV-PT7-SPI-3 coinfected cells
as confirmed by using the inhibitor tunicamycin. The
pparent size of SPI-3 from vaccinia/T7 expression was
educed in the presence of tunicamycin (Fig. 5A, lane 3)
ompared with expression in the absence of the inhibitor
Fig. 5A, lane 1). If differential glycosylation does account
or the apparent size difference for SPI-3 from vaccin-
a/T7 and from the MYX recombinant, then complete
eglycosylation of SPI-3 protein from the two sources
hould generate polypeptides of the same apparent mo-
ecular weight. SPI-3 from VV/T7 and from MYX was
ompared following treatment with peptide-N-glycosi-
ase F (PNGase F), an enzyme that completely removes
ll types of N-glycan chains from glycoproteins. After
omplete digestion with the enzyme, both proteins mi-
rate with an identical mobility of 42 kDa, consistent with
he primary amino acid sequence of SPI-3 (compare
anes 2 and 5 in Fig. 5A). Therefore, differences in gly-
osylation appear to account for the different electro-
horetic mobilities of SPI-3, which in turn are determined
y the virus from which the protein is expressed.
We explored the possibility that the different appar-
nt masses of SPI-3 derived from vaccinia and MYX
nfected cells (Fig. 4) represent differences in how
any potential N-glycosylation sites are utilized. SPI-3
rotein from the supernatants of RK-13 cells infected
ith MYXDSERP1<SPI-3 was partially digested with
NGase F to remove N-linked sugars (Fig. 5B, lanes
–4). Incomplete digestion produces a total of five pro-
ein bands, the smallest of which corresponds in size to
he expected size (42 kDa) of the SPI-3 polypeptide
redicted from the sequence (Fig. 5B). A similar pattern
f five SPI-3 proteins has been seen when the SPI-3
ene is transcribed and translated in vitro in the pres-
nce of canine microsomal membranes (Turner et al.,
b000). Collectively, these results suggest that all four
otential N-linked glycosylation sites in the SPI-3 protein
re utilized during a MYX infection. The increased size of
PI-3 expressed from the MYX recombinant compared
ith VV/T7 expression suggests that N-linked glycans of
reater molecular mass are being added at the four
lycosylation sites in MYX-infected cells; i.e., the ladder
f five bands is more widely spaced from MYX than from
accinia. The different MYX SPI-3 glycosylation pattern
ay be due in part to the addition of sialic acid residues
FIG. 5. Effect of endoglycosidase treatment on SPI-3 isolated from
vaccinia/T7 expression or from MYXDSERP1<SPI-3 infection. (A) Di-
gestion with PNGase F of SPI-3 derived from vTF73/VV-PT7-SPI-3 coin-
fected cells (lanes 1–3, cell pellets) or from MYXDSERP1<SPI-3 (lanes
4–6, supernatants). Lane 1, extract from RK-13 cells coinfected with
VV-PT7-SPI-3 and vTF7-3 (overexpressed SPI-3), untreated with
NGaseF. Lane 2, cellular extract containing overexpressed SPI-3 from
V, digested to completion with 2 units PNGase F. Lane 3, cell extract
ontaining SPI-3 overexpressed in the presence of tunicamycin. Lane
, partially PNGase F-digested SPI-3 from supernatant of
YXDSERP1<SPI-3-infected RK-13 cells, treated with 0.5 units
NGaseF. Lane 5, completely digested SPI-3 from MYXDSERP1<SPI-3
upernatant, treated with 2 units PNGase F. Lane 6, untreated SPI-3
rom MYXDSERP1<SPI-3 supernatant. (B) Partial digestion of secreted
PI-3 from MYXDSERP1<SPI-3 with peptide N-glycosidase F (PNGase
). Supernatants were either untreated (lane 1) or treated with 0.1, 1, or
units PNGase F (lanes 2, 3, and 4, respectively) for 16 h at 37°C
efore immunoblotting with anti-SPI-3 serum.y the MYX-encoded a2,3-sialyltransferase (Jackson et
al., 1999), which is absent from the orthopoxviruses.
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287FUNCTIONAL EXCHANGE OF SERP1 AND SPI-3MYXDSERP1<SPI-3 expresses SPI-3 as a late protein
In the MYXDSERP1<SPI-3 recombinant, the SPI-3
ORF was placed under control of the SERP1 promoter,
which should render expression late and susceptible
to inhibition by viral DNA synthesis inhibitors such as
AraC. Supernatants from RK-13 cells infected with
FIG. 6. Time course of SPI-3 secretion by MYXDSERP1<SPI-3. The
supernatants of RK-13 cells infected with MYXDSERP1<SPI-3 in the
absence or in the presence of AraC were harvested at the times
postinfection indicated above the lanes, concentrated, and immuno-
blotted with anti-SPI-3 serum. Lanes 1, 3, 5, and 7 are from infections
without AraC, and lanes 2, 4, 6, and 8 are from infections with AraC
added at 40 mg/ml. Lanes 1 and 2 are from supernatants removed at 4 h
postinfection; lanes 3 and 4, 8 h p.i.; lanes 5 and 6, 12 h p.i.; lanes 7 and
8, 16 h p.i.
FIG. 7. Primary and secondary lesions produced in rabbits by MYX r
of virus and photographed at days 3, 5, 7, and 10 p.i., as shown above
is from MYXDSERP1<lacZ, the third is from MYXDSERP1<SPI-3, and
followed over time and was representative of other animals in the same expe
Ears showing secondary lesions, photographed with backlighting.MYXDSERP1<SPI-3 either in the presence or in the
absence of AraC were harvested at 4, 8, 12, and 16 h p.i.,
concentrated, and analyzed for SPI-3 expression. SPI-3
synthesis was apparent at 12 and 16 h p.i. in the absence
of the DNA replication inhibitor AraC (Fig. 6, lanes 5 and
7), but absent when AraC was present (Fig. 6, lanes 6
and 8). These results suggest that SPI-3 is indeed ex-
pressed late following infection with MYXDSERP1<SPI-3
as is SERP1 following a wtMYX infection.
Phenotype in infected rabbits of myxoma virus
derivatives expressing SERP1 or SPI-3
To test the ability of SPI-3 to substitute for SERP1 in
MYX virulence, male New Zealand White rabbits (O.
cuniculus) were infected with wtMYX, MYXDSERP1<lacZ,
YXDSERP1<SPI-3, or rwtMYX2 virus. The rabbits were
njected intradermally with 500 PFU in each flank (a total
f 1000 PFU per rabbit) and were monitored on a daily
asis for progression of disease symptoms. Primary le-
ions at the site of inoculation are shown in Fig. 7A, and
econdary lesions in the ears following virus spread are
hown in Fig. 7B.
All of the myxoma viruses caused a small raised lesion
t the inoculation site by day 3 (Fig. 7A). However, after
ay 5, several differences became apparent between
nants. Rabbits were infected intradermally in each flank with 500 PFU
re. The first row of panels is from wtMYX infected rabbits, the second
rth is from rwtMYX2. Each series is of the same primary lesion or earecombi
the figu
the fourimental group. (A) Primary lesions, photographed with ring flash. (B)
288 WANG ET AL.animals infected with the different viruses. For animals
infected with wtMYX or with rwtMYX2, the primary le-
sions developed rapidly, becoming elevated and moist.
Blistering and hemorrhaging of the primary lesions of
wtMYX2 and rwtMYX2 infected rabbits was evident at
day 10. The final sizes of primary lesions for wtMYX and
for rwtMYX2 were from 3.0 to 4.0 cm in diameter. In
contrast, rabbits infected with either MYXDSERP1<lacZ
or MYXDSERP1<SPI-3 had primary lesions that devel-
oped much more slowly (final size of 1.5–2.5 cm), and by
day 7 they were starting to necrose and resolve.
The primary lesions from MYXDSERP1<lacZ or
MYXDSERP1<SPI-3 infections were flat and dry from
day 7 onward, and the central areas of the lesions be-
came covered with a dark purple scab (Fig. 7A). Histo-
logical analysis of primary lesions harvested at 5 days
p.i. showed severe edema and dermal thickening result-
ing from wtMYX or rwtMYX2 infection and much less
pronounced edema and thickening after infection with
MYXDSERP1<lacZ or MYXDSERP1<SPI-3 (data not
shown), consistent with the gross pathology (Fig. 7A).
Secondary lesions, indicative of viremia, were first
noted in the ears of wtMYX and rwtMYX2 infected ani-
mals by day 5 and continued to develop until at day 10
the ears had near confluent hemorrhagic secondary le-
sions (Fig. 7B), with pronounced drooping. Lesions were
also noted at other sites in wtMYX and rwtMYX2 infected
animals including the muzzle and eyelids. In stark
contrast the ears of animals infected with
MYXDSERP1<lacZ or MYXDSERP1<SPI-3 had a much
reduced number of small lesions (Fig. 7B) and did not
droop. Prominent secondary lesions were not observed
at other locations on these animals.
Rabbits infected with wtMYX or with rwtMYX2 devel-
oped all the symptoms of myxomatosis and were indis-
tinguishable. At day 7 all wtMYX and rwtMYX2 animals
had gram-negative infections as evidenced by conjunc-
tivitis (thickened eyelids) and discharge from the eyes
and nose. By day 9, the wtMYX and rwtMYX2 animals
had severe gram-negative infections and some breath-
ing difficulties. On day 10, the wtMYX and rwtMYX2
infected rabbits were moribund and were euthanized
due to the severity of their symptoms. Infection with
MYXDSERP1<lacZ or with MYXDSERP1<SPI-3 resulted
in only slight to mild gram-negative infections, with
no signs of labored breathing. At day 10 the
MYXDSERP1<lacZ and MYXDSERP1<SPI-3 animals
were active and apparently recovering. No significant
differences were seen between rabbits infected with
MYXDSERP1<lacZ or with MYXDSERP1<SPI-3 in pri-
mary or secondary lesions or in the development of
gram-negative infections.
The results clearly indicate that inactivation of the
SERP1 gene in MYXDSERP1<lacZ results in significant
attenuation, confirming that SERP1 is an important viru-
lence factor for MYX (Macen et al., 1993). Replacement ofSERP1 with SPI-3 in MYXDSERP1<SPI-3 generated a
recombinant that was as attenuated as MYXDSERP1<lacZ.
Furthermore, reintroduction of the SERP1 gene into
MYXDSERP1<SPI-3 and removal of the SPI-3 gene gen-
erated a virus (rwtMYX2) that was as lethal as wtMYX,
indicating that an unintended attenuating mutation at a
site distinct from the SERP1 locus had not occurred in
MYXDSERP1<SPI-3. These data provide clear evidence
that SPI-3 is unable to substitute for SERP1 in MYX
pathogenesis, despite the biochemical similarities be-
tween these proteins and the fact that both are secreted
by MYX.
DISCUSSION
Although SERP1 and SPI-3 have been found to resem-
ble one another in their biochemical activities against
proteinases in vitro (Turner et al., 2000), the two proteins
share only 29% amino acid identity. The results pre-
sented here indicate that SERP1 and SPI-3 are unable to
substitute for one another within the context of either
CPV or MYX. SERP1 clearly does not inhibit cell–cell
fusion mediated by a CPV derivative lacking SPI-3 (Fig.
3). SERP1 expression by CPVDSPI-3<SERP1 was early
as judged by resistance to AraC, as expected for tran-
scription from the SPI-3 promoter (Fig. 2). However,
SERP1 synthesized by CPVDSPI-3<SERP1 was secreted
into the medium as it is naturally in wtMYX, unlike SPI-3,
which is not secreted following CPV infection. In the
vaccinia/T7 overexpression system, SPI-3 could be de-
tected in the infected cell pellet but was not present in
the cleared supernatant (Fig. 4), suggesting that SPI-3 is
cytoplasmic or membrane-bound under these condi-
tions. The SPI-3 protein may be associated naturally with
extracellular virus, like the hemagglutinin, which also
inhibits cell fusion (Ichihashi and Dales, 1971) and is
glycosylated (Payne, 1979). Inhibition of cell–cell fusion
by SPI-3 does not require a wild-type sequence within
the RCL (Turner and Moyer, 1995), but may depend on
N-linked glycosylation. Although SERP1 and SPI-3 are
both N-glycosylated (Macen et al., 1993; Turner and
Moyer, 1995), the numbers of potential glycosylation
sites are different for the two proteins (3 for SERP1 and
4 for SPI-3), and their locations within the two proteins
are not conserved (Fig. 1). Secretion of SERP1 or glyco-
sylation differences provide possible explanations as to
why SERP1 does not inhibit cell–cell fusion. In addition a
fusion phenotype has not been reported for SERP1
knockout mutants of either malignant rabbit virus (Upton
et al., 1990) or MYX (Macen et al., 1993) when compared
with the corresponding wild-type viruses.
Expression of SPI-3 by MYXDSERP1<SPI-3 gave rise
to two unexpected findings. First, we had not anticipated
that SPI-3 would be secreted into the medium by
MYXDSERP1<SPI-3 (Fig. 4). This underscores the impor-
tance of viral context in determining localization and
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289FUNCTIONAL EXCHANGE OF SERP1 AND SPI-3ultimately biological activity of a given gene product. Had
the two serpins not been exchanged between the vi-
ruses, it is unlikely that the differential secretion of SPI-3
would have been observed. The reason for the phenom-
enon is of keen interest. The cell association of SPI-3
after infection with orthopoxviruses but not with the MYX
recombinant could reflect either retention of the protein
in orthopoxviruses through interaction(s) with another
viral protein(s) or an effect of MYX on the host cell such
that viral proteins are secreted more efficiently. Clearly
this hypothetical modification to the secretion apparatus
would be predicted not to occur following infection with
either CPV or VV. SERP1 contains a cleavable signal
peptide from residues 1 to 15, and the cleavage position
between Cys-15 and Arg-16 has been confirmed by N-
terminal sequencing (P. Nash and G. McFadden, per-
sonal communication). SPI-3 contains a sequence that
appears by analysis with SignalP (Nielsen et al., 1997) to
be similar, with the predicted signal cleavage site be-
tween Ala-15 and Tyr-16. The signal peptide is presum-
ably removed following insertion of SPI-3 into the
endoplasmic reticulum. We have shown that SPI-3
protein bearing a His-tag at the N-terminus retains the
tag following expression in the VV/T7 system when
residues 1–15 of the wt SPI-3 have been deleted, but the
tag is removed when the putative signal peptide is
present (Turner et al., 2000). SPI-3 secreted from
MYXDSERP1<SPI-3 infected cells was not associated
with extracellular MYX virions (data not shown) and was
functional as an inhibitor of plasmin, uPA, and tPA when
concentrated supernatants were tested (data not
shown).
Second, the apparent size of SPI-3 synthesized by the
MYX recombinant (57 and 55 kDa) was increased com-
pared with that seen for either wtCPV (50 kDa) (Turner
and Moyer, 1995) or following overexpression by VV (50
and 48 kDa) (Fig. 4). The larger size of the SPI-3 protein
synthesized by MYXDSERP1<SPI-3 apparently reflects
differences in N-linked glycosylation in RK-13 cells in-
fected with MYX or with VV (Fig. 5). The recent discovery
of an a2,3-sialyltransferase encoded by MYX is the first
description of a natural virus-encoded glycosyltrans-
ferase (Jackson et al., 1999) and provides a possible
xplanation for the observed size discrepancy. It is very
ossible that SPI-3, after reaction with the GlcNAc-a
1,3/4-fucosyltransferase from the host cell, has been fur-
ther modified by the a2,3-sialyltransferase such that it
ontains additional terminal sialic acid residues on the
arbohydrate chains, hence increasing the apparent mo-
ecular weight of SPI-3 by SDS–PAGE. The MYX MST3N
ene encoding the a2,3-sialyltransferase does not have
a homolog in VV (Jackson et al., 1999).
SPI-3 synthesis by MYXDSERP1<SPI-3 was elimi-
nated by treatment with AraC (Fig. 6), as expected for
expression from the SERP1 promoter at late times during
infection. We do not know how the level of SPI-3 secreted
a
binto the medium by MYXDSERP1<SPI-3 compares with
the natural level of SERP1, but we do know that the timing
and localization of SPI-3 expression by the recombinant
are the same as those seen for SERP1. The finding that
SPI-3 does not substitute for SERP1 in MYX pathogene-
sis (Fig. 7) indicates that the two serpins are fundamen-
tally different, despite their similar inhibition spectrum in
vitro. The true proteinase target(s) for SERP1 and SPI-3 is
almost certainly not plasmin, urokinase, tPA, thrombin, or
factor Xa as the apparent second-order association rates
between SERP1 or SPI-3 and these proteinases are rel-
atively slow, all at or below 105 M21s21 (Nash et al., 1998;
Turner et al., 2000), which is considered the threshold for
physiologically significant interactions (Travis and
Salvesen, 1983). Also MYX and CPV may not encounter
these classical plasma proteinases during natural infec-
tions. Our results strongly suggest that the true target
proteinases for SERP1 and SPI-3 are different. However,
other interpretations are possible. For example, the tar-
get might be the same for the two serpins but the spe-
cies specificity may differ such that SERP1 inhibits the
enzyme from rabbits but SPI-3 does not. In this case
SPI-3 would be expected to inhibit the homologous pro-
teinase from the natural host for CPV, rodents. Our cur-
rent efforts are directed toward determining where SPI-3
is localized in natural infections and finding physiologic
targets for SPI-3 and SERP1.
MATERIALS AND METHODS
Viruses and cells
The wild-type Brighton Red strain of CPV was obtained
from David Pickup (Duke University Medical Center). The
wild-type Lausanne strain of MYX was obtained from
Grant McFadden (J. P. Robarts Research Institute, Lon-
don, Ontario, Canada). CV-1 cells (ATCC CCL-70) and
RK13 cells (ATCC CCL-37) were grown in Gibco BRL
minimum essential medium with 5% fetal bovine serum,
2 mM glutamine, 50 U of penicillin per milliliter, 50 mg of
treptomycin per milliliter, 1 mM sodium pyruvate, and
.1 mM nonessential amino acids.
lasmid constructions
The Escherichia coli gpt gene under control of the VV
7.5 promoter [the P7.5gpt cassette, originally from pTK61-
pt (Falkner and Moss, 1988)] was excised as a 2-kb
coRI fragment from pBS-gptA (Turner and Moyer,
992b). pSPH-ATI/lacZ was constructed and the recom-
inants were selected as described previously (Li et al.,
998).
The scheme for construction of the CPV and MYX
erivatives used is shown in Fig. 1. A recombinant PCR
ethod (Turner and Moyer, 1992b) was used to generate
transfer plasmid in which the SPI-3 ORF was replaced
y the SERP1 coding region and the SPI-3 promoter was
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290 WANG ET AL.retained. The 400-bp region downstream of the SPI-3
gene (SPI-3R) was amplified with the sense primer CD1
(59-GCGTCTAGATATTGTTTATGGATACGGT-39) and the
antisense primer CD2 (59-GCGGAGCTCATTCTCTAGAA-
GATTTTTCA-39). Primers CU1 (59-GCGGGTACCTACAAC-
CGGAAAAAGAAATT-39) and R2 (59-ACGAGGACCA-
GATACTTCATGATTTTATGGTATTAATAA-39) were used to
amplify the region upstream from the SPI-3 ORF, includ-
ing the promoter region (PSPI-3). The underlined portion of
R2 is complementary to the 59 end of the SERP1 coding
region, and the remaining part is complementary to the
sequence of SPI-3 upstream from the initiating ATG (Fig.
1). The SERP1 coding region acted as the central portion
in the recombinant PCR scheme and was amplified with
primers R3 (59-ATGAAGTATCTGGTCCTCGT-39) and R4
(59-GCGTCTAGATTATACAGAGGATACGACAT-39). The PSPI-3
and SERP1 fragments were joined by mixing the purified
DNAs and amplifying with the outside primers (CU1 and
R4). The first two cycles were denaturation at 94°C for 1
min, followed by slow cooling to 37°C (ramp rate of 10
s/°C). The next 12 cycles were 94°C for 1 min, 50°C for
1 min, and 72°C for 2 min. Extension was completed by
a final incubation at 72°C for 10 min. The recombinant
and the downstream flank of the SPI-3 gene were inserted
serially into pBluescript KS(1) (Stratagene) and then veri-
ied by sequencing to produce the plasmid pPSPI-3-SERP1.
he P7.5gpt cassette was inserted into the unique XbaI
restriction enzyme site in pPSPI-3-SERP1 in the same orien-
tation as the SERP1 ORF to create the transfer plasmid
pPSPI-3-SERP1-P7.5gpt.
A plasmid for deleting SERP1 from MYX and inserting
lacZ cassette in its place was constructed as follows.
rimers LP1 (59-GCGGGTACCTCCGTAACAACACGTGT-
TC-39) and LP2 (59-GCGCTCGAGTTAACCCTCAAAAA-
AACGT-39) were used to amplify the 359-bp region
pstream from the SERP1 gene (SERP1L); and RP11 (59-
GCGTCTAGAACGCCCTCACGCCGATCGT-39) and RP2
(59-GCGGAGCTCCATAACGAGACTGGGCATAA-39) were
used to amplify the 563-bp region downstream of the
SERP1 gene (SERP1R). The left part of SERP1R includes
50 bp of the SERP1 39 end coding sequence since this
sequence potentially includes the M-T8 promoter (Fig. 1).
The two fragments were PCR-amplified, serially cloned
into pBluescript KS(1), and sequenced to verify the lack
of errors. A 3.4-kb MscI and PstI fragment consisting of
the lacZ gene driven by the CPV ATI promoter derived
from pSPH-ATI/lacZ (Li et al., 1998) was inserted be-
tween the flanking sequences to create pSERP1-ATI/
lacZ.
A transfer plasmid was generated in which the SERP1
coding region was replaced by the SPI-3 ORF but the
SERP1 promoter was retained. LP1 and C2 (59-TAT-
CAATAACGCAATCATTTAACCCTAAAAAAAACGT-39), in
which the 18 bases at the 59 end are complementary toPI-3 and 20 bases at the 39 end are complementary to
he SERP1 promoter, were used to amplify the left flank- png fragment including the SERP1 promoter. C3 (59-AT-
ATTGCGTTATTGATA-39) and C4 (59-GCGTCTAGATTA-
GGAGATTCTACCTTA-39) were used to amplify the SPI-3
pen reading frame. After the amplification, the two frag-
ents were joined by recombinant PCR as described
bove. After the verification of the sequence, the product
nd the right flank of the SERP1 gene were serially
nserted into pBluescript KS(1) to generate pPSERP1-SPI-3.
he P7.5gpt cassette was inserted into the unique XbaI
estriction enzyme site in the same orientation as SERP1
o create the pPSERP1-SPI-3-p7.5gpt transfer plasmid.
Plasmid pSERP1 containing the SERP1 ORF and natural
lanking sequences was constructed by cloning the PCR
roduct generated from MYX genomic DNA with primers
P1 and RP2. pSERP1 was used to obtain the recon-
tructed wild-type virus rwtMYX2 from MYXDSERP1<SPI-3.
onstruction of virus recombinants
CV-1 or RK13 cells grown to 80% confluence in 60-mm-
iameter dishes were infected at a multiplicity of 0.05,
nd 5 mg plasmid DNA complexed with 30 mg Lipofectin
Gibco BRL) in a total volume of 100 ml was added at the
nd of the 2-h adsorption period. The infected and trans-
ected cells were harvested at 48 h postinfection, and
irus recombinants were obtained by plaquing. Recom-
inant viruses containing the E. coli xanthine-guanine
hosphoribosyltransferase (gpt) gene were selected by
esistance to mycophenolic acid (MPA). Gpt selection
edium contained 2.5 mg of MPA per milliliter, 250 mg of
xanthine per milliliter, and 15 mg of hypoxanthine per
illiliter. For the gpt selection, 3 ml of gpt selection
edium with 5% fetal bovine serum was added following
he infection/transfection procedure. Confluent monolay-
rs of CV-1 or RK13 cells were pretreated for 14 to 24 h
ith gpt selection medium before infection with virus
esulting from the gpt transfections. MPA-resistant
MPAR) plaques were visualized after 3 days by staining
with neutral red (Gibco BRL). To screen for the expres-
sion of LacZ, X-Gal was added to a final concentration of
300 mg/ml in the overlaying agarose after plaque forma-
ion had occurred. MYX recombinants lacking gpt were
elected following infection and transfection of RK-13
ells by plaquing on HGPRT2 HeLa cells (Kerr et al.,
1991) in the presence of 1 mg/ml 6-thioguanine (Isaacs et
al., 1990). In all cases recombinants were plaque purified
at least three times before amplification to produce virus
stocks.
Immunoblot analysis
Infected CV-1 or RK13 cells in 35-mm-diameter wells
were harvested at 20 h p.i. and the cell pellet was
resuspended in 100 ml of cell lysis buffer [100 mM Tris–
HCl (pH 8), 100 mM NaCl, 0.5% Nonidet-P40 (NP-40)]
containing 1.5 mg of Aprotinin per milliliter. For secreted
rotein analysis, the supernatants were harvested from
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291FUNCTIONAL EXCHANGE OF SERP1 AND SPI-3infected cells and centrifuged at 1000g for 10 min to
pellet residual cells. To remove extracellular virus, the
supernatants were centrifuged at 16,000g for 20 min. The
cleared supernatants were concentrated using Cen-
triprep 10 filters (Amicon). Peptide N-glycosidase F
(PNGase F, Roche Molecular Biochemicals) digestions
were performed according to the manufacturer’s instruc-
tions. Concentrated serum-free medium from cells in-
fected with MYXDSERP1<SPI-3 or cell pellets from cells
coinfected with vTF7-3 and VV-PT7-SPI-3 were incubated
ith PNGase F for 16 h at 37°C. The reaction products
ere analyzed by SDS–PAGE and immunoblotting with
nti-SPI-3 serum.
SDS–PAGE protein gels were electroblotted to 0.1-mm-
pore-size nitrocellulose. Blots were probed either with
anti-MBP-SPI-3 rabbit polyclonal antiserum (Turner and
Moyer, 1995) diluted 1:300 or with anti-SERP1 monoclo-
nal antibody at 1:5000 diluted into phosphate-buffered
saline with 0.05% NP-40 and 5% (wt/vol) dried milk, fol-
lowed by horseradish peroxidase (HRP)-conjugated goat
anti-rabbit serum (Fisher Biotech) at 1:5000 or HRP-con-
jugated goat anti-mouse serum at 1:2000. Bound anti-
bodies were detected using enhanced chemilumines-
cence reagents (Amersham).
Infection of rabbits with myxoma virus derivatives
Male New Zealand White rabbits (O. cuniculus) were
obtained from Myrtle Rabbitry, Inc. (Thompson Station,
Tennessee) and housed in level C containment facilities.
Each rabbit was injected intradermally with 500 PFU/hind
flank (total of 1000 PFU per rabbit) of wtMYX,
MYXDSERP1<lacZ, MYXDSERP1<SPI-3, or rwtMYX2 vi-
rus. Eight rabbits were infected for each virus group with
the exception that only three rabbits were infected with
rwtMYX2. Rabbits were monitored on a daily basis for
the appearance and progression of disease symptoms.
Primary lesions (at the injection site) and secondary
lesions in the ears were photographed at regular inter-
vals. On days 1, 3, and 5 postinfection, two rabbits from
the wtMYX, MYXDSERP1<lacZ, and MYXDSERP1<SPI-3
infection groups were euthanized by intravenous admin-
istration of Euthasol and necropsies were performed.
The remaining animals, including those infected with
rwtMYX2, were sacrificed on day 10 postinfection.
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